News

Article

Clinical Quiz: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Check out the first in our series of quizzes testing your knowledge the ESC/EAS 2019 guidelines on dyslipidemia. this quiz focuses on basic lipid management principles!

The management of dyslipidemia has undergone a transformation since the turn of the century, driven by advances in understanding pathophysiology as well as developments in pharmacological therapies.

For decades, statins were not only the centerpiece, but often the only option for many patients who struggled with lipid disorders. While their role as a mainstay in therapy has persisted through time as a result of their affordability, efficacy, and established safety profile, the advent of new therapies has redefined what is considerable an optimal approach to management of dyslipidemia for many. With such a rapid rate of advancements, the release of updated guidance has become paramount.

In this clinical quiz, we test your knowledge of basic lipid management principles from the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk.

Of note, this is the first in a series of 4 quizzes based on these guidelines. Check back for more quizzes on risk assessment, pharmacotherapy, and nonpharmacologic interventions in the coming weeks!

Quizzes in this series:

Quiz 1: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 2: Risk Assessment and Stratification from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 3: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

Quiz 4: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

According to the 2019 ESC/EAS guidelines, what is the target LDL-C level for patients with documented atherosclerotic cardiovascular disease (ASCVD) who are considered very high risk?


Reference:

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.